Coronavirus Pandemic
Logo
 

Covid-19: India approves Cadila's 3-dose needle-free vaccine

Reuters/Bengaluru
Filed on August 20, 2021

(AP file)

Cadila's vaccine will be the second home-grown shot to get emergency approval in India.


The Indian drug regulator's subject expert committee has recommended emergency use approval for Zydus Cadila's three-dose Covid-19 vaccine, CNBC-TV18 reported on Friday, citing sources.

The committee added that Zydus needs to submit additional data for the 2-dose regimen of its vaccine, CNBC-TV18 said in a tweet.

The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorisation of the vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6 per cent in a late-stage trial of more than 28,000 volunteers nationwide.

If approved, Zydus Cadila's vaccine will be the second home-grown shot to get emergency authorisation in India after Bharat Biotech's Covaxin.

Zydus Cadila and India's drug regulator did not immediately respond to a Reuters request for comment.





ERROR: Macro /ads/dfp-ad-article-new is missing!
MORE FROM Coronavirus Pandemic
MORE FROM Khaleej Times
CurrentRequestUnmodified: /coronavirus-pandemic/covid-uae-to-start-sinopharm-vaccine-production-from-april macro_action: article, macro_profile: ,1913,1000 macro_adspot:
 
 
 
 
 
KT App Download
khaleejtimes app

All new KT app
is available
for download:

khaleejtimes - android khaleejtimes - ios khaleejtimes - HUAWEI AppGallery